neutral
2h agoIndian pharma shares gain momentum as US legislation reshapes biotech landscape
Indian pharmaceutical stocks moved sharply higher on December 19 after the US Senate cleared the Biosecure Act as part of the fiscal 2026 National Defense Authorization Act. The legislation restricts certain Chinese biotech companies from accessing US federal funding, a move investors believe could redirect global outsourcing and contract manufacturing demand.
neutral
2h agoIndian pharma shares gain momentum as US legislation reshapes biotech landscape
Indian pharmaceutical stocks moved sharply higher on December 19 after the US Senate cleared the Biosecure Act as part of the fiscal 2026 National Defense Authorization Act. The legislation restricts certain Chinese biotech companies from accessing US federal funding, a move investors believe could redirect global outsourcing and contract manufacturing demand.
1 min read
51 words
Pharma stocks rallied after the US Senate passed the Biosecure Act, with investors betting Indian drugmakers could benefit from reduced Chinese competition and shifting global supply chains.
Indian pharmaceutical stocks moved sharply higher on December 19 after the US Senate cleared the Biosecure Act as part of the fiscal 2026 National Defense Authorization Act. The legislation restricts certain Chinese biotech companies from accessing US federal funding, a move investors believe could redirect global outsourcing and contract manufacturing demand.
Indian pharmaceutical stocks moved sharply higher on December 19 after the US Senate cleared the Biosecure Act as part of the fiscal 2026 National Defense Authorization Act. The legislation restricts certain Chinese biotech companies from accessing US federal funding, a move investors believe could redirect global outsourcing and contract manufacturing demand.
Dec 20, 2025 • 07:50